Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.

University of Nairobi126 enrolled

Overview

Null hypothesis; The efficacy of Enhancin\]Co-Amoxiclav given as a single intravenous dose at induction is not better than a five days oral course of the same given postoperatively in reducing postoperative morbidity after adenotonsillectomy.

Adenotonsillectomy results in morbidity that is reduced by the use of antibiotics.This study had the sole objective of comparing two route of administration to see which has superior results.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

126

Conditions

Adenotonsillar Hypertrophy,Under 12 Years.

Interventions

EnhancinDRUG

Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent. Oral dose of the same at the same dosage for the active comparator arm.

Eligibility

Sex: ALLMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients below 12year scheduled to undergo adenotonsillectomy whose parents or guardians give consent for recruitment into the study. Exclusion Criteria: * Non consenting parents or guardians. Antibiotic use in the week preceding surgery. Patients with co mordities. Known allergies to Co-amoxiclav. Patients who develop complication that warrant change of antibiotic.

Locations (1)

Kenyatta National Hospital.

Nairobi, Nairobi County, Kenya

Outcomes

Primary Outcomes

POSTOPERATIVE FEVER

Temperature monitored at 1st ,4th and 7th postoperative days.

Time frame: OPERATION DAY TO 7 DAYS POSTOPERATIVELY

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.